Alexander A. Zukiwski - Sep 7, 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc. (CASI)

Role
EVP and Chief Medical Officer
Signature
/s/Alexander A. Zukiwski
Stock symbol
CASI
Transactions as of
Sep 7, 2022
Transactions value $
$0
Form type
4
Date filed
9/9/2022, 04:01 PM
Previous filing
Dec 6, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CASI Employee Stock Option (Right to Buy) Award $0 +3K $0.00 3K Sep 7, 2022 Common Stock 3K $15.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 25, 2021, subject to approval at the June 15, 2021 shareholders meeting, the reporting person was granted these stock options that vest upon achievement of certain performance based conditions. The performance based condition was satisfied on September 7, 2022, resulting in vesting of the options.
F2 On June 1, 2022, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split"). The number of stock options and the exercise price reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.